Communiqués Cerus Corporation

Actions

CERS

US1570851014

Equipement, fournitures et distribution médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 18/06/2026			Varia. 5j.	Varia. 1 janv.
2,700 ^USD	+5,06%		+5,47%	+31,07%

27/05	Bradley L. Radoff annonce son intention de s'abstenir lors du vote pour les administrateurs de Cerus Corporation	CI
01/05	Transcript : Cerus Corporation, Q1 2026 Earnings Call, Apr 30, 2026

Communiqués

17/06	Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress	BU
08/06	Cerus Corporation Closes New Debt Facility of Up to $110 Million	BU
30/04	Cerus: Q1 Earnings Snapshot	AQ
30/04	Cerus Corporation Announces First Quarter 2026 Financial Results	BU
27/04	Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System	BU
23/04	Cerus : Audit Committee Charter(Revised March 2026)	PU
16/04	Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026	BU
16/03	Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer	BU
02/03	Cerus: Q4 Earnings Snapshot	AQ
02/03	Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results	BU
23/02	Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference	AQ
20/02	Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference	BU
17/02	Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026	BU
23/01	DRK Blood Donation Service Baden-Wurttemberg, Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus INTERCEPT Blood System in Routine Clinical Practice	AQ
22/01	DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus’ INTERCEPT™ Blood System in Routine Clinical Practice	BU
11/01	Cerus : Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook	PU
11/01	Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook	BU
10/12	Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America	BU
06/11	Cerus: Q3 Earnings Snapshot	AQ
06/11	Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance	BU
21/10/25	Cerus Corporation Announces Abstracts and Industry Workshop on IFC at the 2025 AABB Annual Meeting	BU
16/10/25	Cerus Corporation to Release Third Quarter 2025 Financial Results on November 6, 2025	BU
25/08/25	The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions	BU
21/08/25	Cerus Corporation to Participate in the Cantor Global Healthcare Conference 2025	BU
05/08/25	Cerus: Q2 Earnings Snapshot	AQ